Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia

Naoki Mori; Kentaro Yoshinaga; Kaori Tomita; Mari Ohwashi; Toshiaki Kondoh; Hanae Shimura; Yan Hua Wang; Masayuki Shiseki; Michiko Okada; Toshiko Motoji

doi:10.1016/j.leukres.2010.08.002

Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia

Naoki Mori^*, Kentaro Yoshinaga, Kaori Tomita, Mari Ohwashi, Toshiaki Kondoh, Hanae Shimura, Yan Hua Wang, Masayuki Shiseki, Michiko Okada, Toshiko Motoji

^*此作品的通讯作者

科研成果: 期刊稿件 › 文章 › 同行评审

18 引用（Scopus）

摘要

We performed methylation specific PCR analysis on the RIZ1 promoter in MDS and AML. Methylation was detected in 17 of 34 MDS (50%) and 22 of 72 AML (31%) (p= 0.053). Methylation was detected in eleven of 17 secondary AML from MDS (65%), and eleven of 55 de novo AML (20%) (p= 0.0005). Bisulfite sequence revealed methylation at many CpG sites in the promoter. Decreased RIZ1 expression was accompanied by methylation in six of nine samples examined, while it was also observed in seven of 13 without methylation. Treatment of AML cells, that have RIZ1 methylation, with 5-Aza-dC, induced growth suppression with RIZ1 restoration. Our results suggest that the RIZ1 gene is inactivated in MDS and AML in part by methylation, whereas another mechanism should be involved in others.

源语言	英语
页（从-至）	516-521
页数	6
期刊	Leukemia Research
卷	35
期	4
DOI	https://doi.org/10.1016/j.leukres.2010.08.002
出版状态	已出版 - 4月 2011
已对外发布	是

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1016/j.leukres.2010.08.002

其它文件与链接

链接到 Scopus 的出版物

引用此

@article{1fef594c4e5c4ec0b462ab65b2c655be,

title = "Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia",

abstract = "We performed methylation specific PCR analysis on the RIZ1 promoter in MDS and AML. Methylation was detected in 17 of 34 MDS (50%) and 22 of 72 AML (31%) (p= 0.053). Methylation was detected in eleven of 17 secondary AML from MDS (65%), and eleven of 55 de novo AML (20%) (p= 0.0005). Bisulfite sequence revealed methylation at many CpG sites in the promoter. Decreased RIZ1 expression was accompanied by methylation in six of nine samples examined, while it was also observed in seven of 13 without methylation. Treatment of AML cells, that have RIZ1 methylation, with 5-Aza-dC, induced growth suppression with RIZ1 restoration. Our results suggest that the RIZ1 gene is inactivated in MDS and AML in part by methylation, whereas another mechanism should be involved in others.",

keywords = "Acute myeloid leukemia, Epigenetics, Methylation, Myelodysplastic syndrome, RIZ1, Tumor suppressor gene",

author = "Naoki Mori and Kentaro Yoshinaga and Kaori Tomita and Mari Ohwashi and Toshiaki Kondoh and Hanae Shimura and Wang, {Yan Hua} and Masayuki Shiseki and Michiko Okada and Toshiko Motoji",

year = "2011",

month = apr,

doi = "10.1016/j.leukres.2010.08.002",

language = "English",

volume = "35",

pages = "516--521",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "4",

}

TY - JOUR

T1 - Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia

AU - Mori, Naoki

AU - Yoshinaga, Kentaro

AU - Tomita, Kaori

AU - Ohwashi, Mari

AU - Kondoh, Toshiaki

AU - Shimura, Hanae

AU - Wang, Yan Hua

AU - Shiseki, Masayuki

AU - Okada, Michiko

AU - Motoji, Toshiko

PY - 2011/4

Y1 - 2011/4

N2 - We performed methylation specific PCR analysis on the RIZ1 promoter in MDS and AML. Methylation was detected in 17 of 34 MDS (50%) and 22 of 72 AML (31%) (p= 0.053). Methylation was detected in eleven of 17 secondary AML from MDS (65%), and eleven of 55 de novo AML (20%) (p= 0.0005). Bisulfite sequence revealed methylation at many CpG sites in the promoter. Decreased RIZ1 expression was accompanied by methylation in six of nine samples examined, while it was also observed in seven of 13 without methylation. Treatment of AML cells, that have RIZ1 methylation, with 5-Aza-dC, induced growth suppression with RIZ1 restoration. Our results suggest that the RIZ1 gene is inactivated in MDS and AML in part by methylation, whereas another mechanism should be involved in others.

AB - We performed methylation specific PCR analysis on the RIZ1 promoter in MDS and AML. Methylation was detected in 17 of 34 MDS (50%) and 22 of 72 AML (31%) (p= 0.053). Methylation was detected in eleven of 17 secondary AML from MDS (65%), and eleven of 55 de novo AML (20%) (p= 0.0005). Bisulfite sequence revealed methylation at many CpG sites in the promoter. Decreased RIZ1 expression was accompanied by methylation in six of nine samples examined, while it was also observed in seven of 13 without methylation. Treatment of AML cells, that have RIZ1 methylation, with 5-Aza-dC, induced growth suppression with RIZ1 restoration. Our results suggest that the RIZ1 gene is inactivated in MDS and AML in part by methylation, whereas another mechanism should be involved in others.

KW - Acute myeloid leukemia

KW - Epigenetics

KW - Methylation

KW - Myelodysplastic syndrome

KW - RIZ1

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=79952360446&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2010.08.002

DO - 10.1016/j.leukres.2010.08.002

M3 - Article

C2 - 20828818

AN - SCOPUS:79952360446

SN - 0145-2126

VL - 35

SP - 516

EP - 521

JO - Leukemia Research

JF - Leukemia Research

IS - 4

ER -

Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia

摘要

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此